NASDAQ · Medical - Devices
CERS (CERS) Stock
$2.32
+2.20%
NASDAQ: CERS
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
Business Wire · Jun 17, 2026
Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M
Insider Monkey · Jun 16, 2026
Cerus Corporation Closes New Debt Facility of Up to $110 Million
Business Wire · Jun 8, 2026
Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?
Zacks · Jun 4, 2026
Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG
Insider Monkey · May 23, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.40%
Institutions Held73.30%
Institutions Float Held75.89%
Peer Comparison
About CERS
CERS is led by CEO William Greenman, employs 614 people, headquartered in US, publicly traded since 1997.
CERS stock trades at $2.32 with a market capitalization of $467.54M. The stock is valued at a price-to-earnings (P/E) ratio of -34.25, price-to-book of 8.58, price-to-sales of 2.46. Over the past 52 weeks the stock has ranged between $1.15 and $3.44, and currently trades 32.6% below its 52-week high.
On profitability, CERS generates a return on equity (ROE) of -25.00%, return on capital employed of -55.38%, an operating margin of -17.48%, a net profit margin of -4.29%.